Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 11:44 AM ET

Pharmaceuticals

Company Overview of Provectus Biopharmaceuticals, Inc.

Company Overview

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its product line includes PV-10, which is in Phase III study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. The company is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and sev...

7327 Oak Ridge Highway

Knoxville, TN 37931

United States

Founded in 2002

4 Employees

Phone:

866-594-5999

Fax:

866-998-0005

Key Executives for Provectus Biopharmaceuticals, Inc.

Chairman, Chief Executive Officer, Chief Executive Officer of Xantech and Director of Xantech
Age: 63
Total Annual Compensation: $500.0K
President, Director, President of Xantech and Director of Xantech
Age: 57
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corporate Treasurer and Secretary
Age: 56
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice President
Age: 52
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

Provectus Biopharmaceuticals, Inc. Key Developments

Provectus Biopharmaceuticals, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:00 PM

Provectus Biopharmaceuticals, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 03:00 PM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States. Speakers: Peter R. Culpepper, Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corporate Treasurer and Secretary.

Provectus Biopharmaceuticals Confirms First Patients Dosed in Trials of PV-10 for Melanoma

Provectus Biopharmaceuticals, Inc. confirmed that patients have been dosed in both its Phase 3 clinical trial of PV-10, Provectus’ novel investigational drug for cancer, for Stage III locally advanced cutaneous melanoma and its Phase 1b/2 clinical trial of PV-10 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with Stage IV melanoma. In addition, the Company confirmed that it continues to enroll patients in all of its active oncology studies.

Provectus Biopharmaceuticals, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-13-2016 03:30 PM

Provectus Biopharmaceuticals, Inc. Presents at 8th Annual Biotech Showcase Investor Conference 2016, Jan-13-2016 03:30 PM. Venue: Parc 55 San Francisco, 55 Cyril Magnin Street, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Vapogenix, Inc. United States
RxBio Holdings, Inc. United States
In-House Pharmacies, Inc. United States
Jason Enterprises, Inc. United States
Veritas Research Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Provectus Biopharmaceuticals, Inc., please visit www.pvct.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.